ProteoTech, Inc., also known as Proteoglycan Technologies, Inc., operates as a drug development company in the United States. The company offers therapeutics and diagnostics for amyloid diseases. Its products include Exebryl-1, a molecule compound to prevent the formation and accumulation of the soluble and insoluble forms of beta-amyloid protein, as well as amyloid plaques found in Alzheimer's brains of disease victims; PeptiClere, a nasal spray for the treatment of Alzheimer's disease; Synuclere for the treatment of Parkinson's disease; and Systebryl, a small molecule compound for the treatment of systemic amyloidosis associated with type 2 diabetes. ProteoTech, Inc. was founded in 1996 and is headquartered in Kirkland, Washington.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Cognitive Clarity, Inc. engages in the research and development of a line of memory supplements that target brain plaques and tangles that accumulate during normal aging. Its products include Percepta, percepta Sport and Percepta Professional. The company was founded by Alan Snow and Rudolph Tanzi in 2015 and is headquartered in Edmonds, WA.

TREVENTIS Corporation is dedicated to treating and preventing protein misfolding diseases. We utilize a proprietary, patent-pending discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our lead program focuses on anti-misfolding small molecules in tauopathy (3R, 4R, familial mutations and mixed) with relevance to Alzheimer’s disease. We have further CCM-driven efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Part of Perrigo Co. Plc, Neuralab Ltd. is an Irish company. The firm prepares pharmaceutical products.

Alterity Therapeutics has developed a proprietary library of class-leading chemical compounds. This library is combined with a drug development program to explore novel therapeutics in multiple disease indications. The scientific focus of the company is upon neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases.

Elan Pharma International Ltd., a subsidiary of Perrigo Co. Plc, is a company headquartered in South San Francisco, CA, that develops, manufactures and distributes pharmaceutical products.

BSIM’s mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and related pathologies that represent important and unmet medical needs. Our products are directed to a group of rare, hereditary and fatal pathologies commonly addressed to as Transthyretin Amyloidoses (hATTR). We are developing drug candidates that fit within distinct target-product profiles for the treatment of a broader range of hATTR manifestations, including central nervous system symptoms (e.g. seizures, stroke-like events, progressive dementia) and oculopathy (e.g. vitreous opacities, glaucoma).

CSL Limited is a public company which is a parent company of the CSL Group. CSL business activities operate in the Human Health, JRH Biosciences, Animal Health and ZLB Plasma Services operations. CSL limited develops, manufactures and markets pharmaceutical products of biological origin. The company' s business is: - Health care; - Life-saving products derived from human plasma; - Pharmaceuticals and diagnostics essential to health; - Cell culture reagents for the pharmaceutical industry; - Veterinary vaccines and diagnostics to protect livestock and companion animals.

Fuence produces nanotech products, Bacterial fermentation, unique purification technologies, manufacturing of applied products, etc.

Neotope Biosciences Ltd. provides biological research services. The company is headquartered in South San Francisco, CA.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.

Alzinova AB is Swedish biotechnology enterprise engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The company was founded in 2011 by the inventors of the AβCC peptide™ technology (patent pending) and MIVAC Development AB in close collaboration with the holding company at the University of Gothenburg in Sweden, GU Ventures AB. The proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities towards several ends, including the discovery and development of novel therapeutics, research tools and services that enhance productivity within Alzheimer’s disease research. Alzinova is exploiting the unique properties of this non-fibrillogenic technology to develop therapeutics and diagnostics otherwise unavailable when using fibrillogenic peptides. The company focuses on development of a unique highly specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.

Misfolding Diagnostics, Inc. is an American private company located in San Diego, CA. The firm operates as a biotechnology company. It was founded by Jeffery W. Kelly.